BioLytical Receives Innovative Technology Contract from Vizient for Rapid HIV Test

RICHMOND, BC, Feb. 21, 2017 /PRNewswire/ – bioLytical Laboratories, a world leader in rapid infectious disease tests, today announced that it has received an Innovative Technology contract from Vizient, Inc., the largest member-owned health care company in the country. The contract was based on a recommendation of INSTI® HIV-1/HIV-2 Antibody Test by hospital representatives with expertise in this category who serve on one of Vizient’s member-led councils. Innovative Technology contracts are reserved for technologies that demonstrate an ability to enhance clinical care or patient safety, and those that improve an organization’s care delivery and business model.

“We are very pleased to receive this award and to offer Vizient’s members and their healthcare professionals the benefits of our rapid point of care HIV test,” said Robert Mackie, bioLytical’s President. “This award is a testament to our strong focus on bringing innovative technologies and products to market and further demonstrates our commitment to improving patient care in the United States and support the CDC guidelines, which recommend HIV screening be a part of routine clinical care in all health-care settings.”

“Due to the number of products and services being released and marketed as ‘innovative’, member hospitals truly value the thorough innovative technology review process in place at Vizient to help them identify products worth further evaluation at their own facilities,” said Debbie Archer, Director of Procurement and leader of Vizient’s Innovative Technology program for suppliers. “After a full review of the INSTI HIV Test, Vizient’s member council agreed this solution offers unique and incremental benefit over other products available on the market today, and recommended it for an Innovative Technology contract. We are pleased to award this new contract to bioLytical.”

The INSTI HIV-1/HIV-2 Rapid Antibody Test is a rapid in vitro qualitative test for the detection of antibodies to Human Immunodeficiency Virus Type 1 and Type 2 in human whole blood, fingerstick blood, or plasma. The test is CLIA waived and intended for use by personnel in a variety of settings such as hospitals, clinical laboratories, community health settings and physician offices as a screening assay capable of providing test results in as little as 60 seconds. The INSTI test kit has a unique immunofiltration “flow-through” design that enables detection of HIV in as little as 21 days after infection, leading to accelerated, early and accurate diagnosis. In HIV antibody test devices that do not detect IgM antibodies, it can take as long as two months following infection for those tests to become positive.

‍